The new supplement is designed to boost male testosterone levels, increase circulation and support an increased libido without the cost and side effects of prescription drugs, the company said.
Like other supplements planned for the company’s Pure Plus brand, this new one will be infused with a Bio-energy boost which will modify the supplement’s ingredients of the subatomic level, enhancing their properties and increasing their power, NTRR said.
Medtronic seeks expanded US approvals for Hugo robotic surgery system
MiniMed expands Abbott partnership for dual glucose-ketone diabetes sensors
Lupin and Natco secure US FDA approval for generic Eribulin Mesylate Injection
Luminopia agrees international licensing deal for paediatric amblyopia treatment in Japan
FDA accepts Genentech's giredestrant application for early-stage breast cancer
Amgen receives EU marketing authorisation for IMDYLLTRA in ES-SCLC
Haisco receives US FDA approval for anaesthetic Cipepofol
Hanmi signs licensing deal with Lilly for sonefpeglutide
FDA approves TREMFYA label expansion
GSK reports positive phase III data for bepirovirsen in chronic hepatitis B
Sanofi's venglustat receives FDA priority review for type 3 Gaucher disease
CellCarta partners with Sonic Healthcare to commercialise companion diagnostics through Lab Network
Ribo submits Phase 2 trial application for RBD1119 to European regulator
US FDA extends review timeline for AstraZeneca's camizestrant application
Orsini to chosen as contracted specialty pharmacy for Gilead's Hepcludex (bulevirtide-gmod)